<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05623033</url>
  </required_header>
  <id_info>
    <org_study_id>WPZhu</org_study_id>
    <nct_id>NCT05623033</nct_id>
  </id_info>
  <brief_title>The Predictive Value of Dynamic Changes of CD4+T Lymphocytes in Primary Nephrotic Syndrome With Infection</brief_title>
  <official_title>The Predictive Value of Dynamic Changes of CD4+T Lymphocytes in Primary Nephrotic Syndrome With Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fifth Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangdong traditional Chinese medicine hospital, Zhuhai</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fifth Affiliated Hospital, Sun Yat-Sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this observational study is to test whether the dynamic changes of CD4+T&#xD;
      lymphocytes can predict infections in patients with primary nephrotic syndrome . The main&#xD;
      questions it aims to answer are:&#xD;
&#xD;
        -  whether the dynamic changes of CD4+T lymphocytes can predict infections in patients with&#xD;
           primary nephrotic syndrome&#xD;
&#xD;
        -  effect of different immunosuppressive therapy on the number and function of T lymphocyte&#xD;
           subsets in patients with primary nephrotic syndrome&#xD;
&#xD;
      Participants will be divided into infection group and non-infection group according to&#xD;
      whether they are infected&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 16, 2022</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Dynamic changes of CD4+T cells</measure>
    <time_frame>3 years after the project starts</time_frame>
    <description>Whether the change of CD4+T lymphocytes count can predict infections in patients with primary nephrotic syndrome</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">156</enrollment>
  <condition>Nephrotic Syndrome</condition>
  <condition>Infections</condition>
  <condition>Lymphocyte</condition>
  <arm_group>
    <arm_group_label>infection group</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>non-infection group</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>The study is an observational study without intervention</intervention_name>
    <description>The study is an observational study without intervention</description>
    <arm_group_label>infection group</arm_group_label>
    <arm_group_label>non-infection group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients with primary nephrotic syndrome&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 14 years and&lt;75 years.&#xD;
&#xD;
          2. It meets the diagnostic criteria of primary nephrotic syndrome, i.e. a. A large amount&#xD;
             of proteinuria (24h urine protein quantity &gt; 3.5g/d); b. Hypoalbuminemia (liver&#xD;
             function: albumin&lt;30g/L); c. Edema; d. The blood lipid is elevated. Among them, item a&#xD;
             and b are necessary conditions for diagnosis.&#xD;
&#xD;
          3. Nephrocentesis pathology indicates the pathological type of nephrotic syndrome&#xD;
             (minimal change glomerulonephritis, membranous nephropathy, focal segmental&#xD;
             glomerulonephritis, membranous proliferative glomerulonephritis, mesangial&#xD;
             proliferative glomerulonephritis).&#xD;
&#xD;
          4. Glucocorticoids or corticosteroids combined with immunosuppressants should be used&#xD;
             clinically.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Secondary nephrotic syndrome, such as secondary to systemic lupus erythematosus,&#xD;
             hepatitis B, hepatitis C, tumor, organic solvent , heavy metal poisoning, etc.&#xD;
&#xD;
          2. Patients with tumor and chronic infectious diseases, such as HIV infection, cardiac&#xD;
             insufficiency, acute hepatitis, transaminase increase more than twice the normal&#xD;
             value, deep vein thrombosis.&#xD;
&#xD;
          3. The subjects were pregnant and lactating women.&#xD;
&#xD;
          4. Patients with serious primary diseases such as heart, brain, liver and hematopoietic&#xD;
             system.&#xD;
&#xD;
          5. Those who can not cooperate, such as the mentally ill.&#xD;
&#xD;
          6. It is known that it is allergic to or has contraindications to any component in&#xD;
             glucocorticoid, FK506, MMF and CTX.&#xD;
&#xD;
          7. Serum creatinine (SCR) &gt; 265.2 μ mol/L（3mg/dl）。&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wei Ping Zhu</last_name>
    <phone>13926927805</phone>
    <phone_ext>0756-2528701</phone_ext>
    <email>zhuwp@mail.sysu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>the fifth affiliated hospital of SUN YAT-SEN university</name>
      <address>
        <city>Zhuhai</city>
        <state>Guangdong</state>
        <zip>519000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ZHU weiping, associate chief physician</last_name>
      <phone>13926927805</phone>
      <phone_ext>13926927805</phone_ext>
      <email>292428893@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 7, 2022</study_first_submitted>
  <study_first_submitted_qc>November 17, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 21, 2022</study_first_posted>
  <last_update_submitted>November 20, 2022</last_update_submitted>
  <last_update_submitted_qc>November 20, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Nephrotic Syndrome</mesh_term>
    <mesh_term>Nephrosis</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

